Tianyin granted production license for diabetes drug Gliclazide by China's SFDA

Tianyin Pharmaceutical (NYSE Amex: TPI), a China-based pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, says it has received a production license for its anti-diabetic drug Gliclazide Tablets (80mg formulation) from China's State Food and Drug Administration (SFDA).

The company expects to bring the drug, which was approved for marketing in China last month, to the market next month. Gliclazide is an oral anti-diabetic drug used for the control of hyperglycemia in gliclazide-response diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset. It is used when proper dietary adjustment and exercise fail to reduce the blood sugar content or for conditions that are not suitable for insulin therapy.

The drug is listed in the National Medical Reimbursement List (NMRL) of China. The issuance of approval and production license brought Tianyn’s portfolio to 58 products in total, 24 of which are reimbursed by China's Government Medical Insurance Program.